Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Document (FAD) recommending REMICADE (infliximab), HUMIRA (adalimumab) and SIMPONI (golimumab), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis (UC) in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.

16 Dec 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.

27 Nov 2014

Researchers say that promoting healthy gut microbiota can help treat metabolic syndrome

Promoting healthy gut microbiota, the bacteria that live in the intestine, can help treat or prevent metabolic syndrome, a combination of risk factors that increases a person's risk for heart disease, diabetes and stroke, according to researchers at Georgia State University and Cornell University.

24 Nov 2014

Salivary mucins protect teeth from cariogenic bacterium

Salivary mucins, key components of mucus, actively protect the teeth from the cariogenic bacterium, Streptococcus mutans, according to research published ahead of print in Applied and Environmental Microbiology. The research suggests that bolstering native defenses might be a better way to fight dental caries than relying on exogenous materials, such as sealants and fluoride treatment, says first author Erica Shapiro Frenkel, of Harvard University, Cambridge, MA.

11 Nov 2014

Oats play important role in human health

According to a new, wide-reaching collection of scientific reviews published in the October 2014 supplement issue of the British Journal of Nutrition, oats may play an important role in improving satiety, diet quality and digestive, cardiovascular and general metabolic health.

30 Oct 2014

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.

28 Oct 2014

Research could pave way for more effective drugs to treat inflammation

Six Case Western Reserve scientists are part of an international team that has discovered two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis.

25 Oct 2014

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms.

21 Oct 2014

New oral biologic medication successfully treats precancerous intestinal inflammation

An oral biologic medication has successfully treated chronic, precancerous inflammation in the intestine, according to results of an animal study authored by an MD/PhD student in the University at Buffalo School of Medicine and Biomedical Sciences.

16 Oct 2014

New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

New research shows that the majority of patients with the challenging inflammatory bowel disease, ulcerative colitis (UC), state that the three biggest impacts of the disease on their lives are on their emotional state (in terms of depression, anger or anxiety levels) (76%), ability to get adequate rest/sleep (75%), and taking sick days off work (70%). Those who have had a colectomy (removal of the colon) were more likely to suffer from these impacts.

14 Oct 2014

Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

The Kenneth Rainin Foundation announced today that it will grant $2.2 million to scientists to conduct Inflammatory Bowel Disease (IBD) research. The Rainin Foundation offers support for cutting-edge projects that typically are not eligible for funding from more traditional sources due to their ground-breaking, pioneering nature.

14 Oct 2014

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015.

7 Oct 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie today announced results from a Phase 3 pivotal study demonstrating that HUMIRA® (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules.

11 Sep 2014

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

8 Sep 2014

Researchers discover genetic factors involved in development of early-onset ulcerative colitis

UCLA researchers were part of a team that has discovered the interplay of several genetic factors that may be involved in the development of early-onset ulcerative colitis, a severe type of inflammatory bowel disease.

4 Sep 2014

Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

One in every 200 Ontarians has been diagnosed with inflammatory bowel disease (IBD), with the number of people living with the disease increasing by 64 per cent between 1999 and 2008, according to a study by researchers at the Institute for Clinical Evaluative Sciences, the Children's Hospital of Eastern Ontario, and the Ottawa Hospital Research Institute.

29 Aug 2014

Yale University researchers identify bacterial culprits that drive IBD

Yale University researchers have identified a handful of bacterial culprits that may drive inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis, using patients' own intestinal immune responses as a guide.

29 Aug 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2014

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

NICE recommends REMICADE, HUMIRA and SIMPONI therapies for patients with ulcerative colitis

iCo Therapeutics announces corporate update and Q3 2014 financial results

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Researchers say that promoting healthy gut microbiota can help treat metabolic syndrome

Salivary mucins protect teeth from cariogenic bacterium

Oats play important role in human health

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Research could pave way for more effective drugs to treat inflammation

Obeticholic acid drug shows promise against bile acid diarrhoea

New oral biologic medication successfully treats precancerous intestinal inflammation

New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Researchers discover genetic factors involved in development of early-onset ulcerative colitis

Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

Yale University researchers identify bacterial culprits that drive IBD

Study finds a host of new clues on gene-environment interactions in Crohn's disease

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in